Морфологические и молекулярно-биологические факторы прогноза рака мочевого пузыря
Диссертация
Важную роль в развитии опухоли, несомненно, играет внеклеточный матрикс (ВКМ). Матриксные металлопротеиназы (ММР) обеспечивают проницаемость ВКМ при инвазии и метастазировании рака. Для всех ММР существуют соответствующие специфические ингибиторы — тканевые ингибиторы металлопротеиназ (TIMP). Эти энзимы принимают активное участие в неопластической трансформации, обеспечивая клеткам опухоли… Читать ещё >
Список литературы
- Аль Шукри С. Х., Ткачук В. Н. Опухоли мочевого пузыря в пожилом и старческом возрасте.// Издательство СПбГМУ.- СПб.- 1999.- С.115- 163.
- Аничков Н.М., Толыбеков A.C. Уротелий норма, воспаление, опухоль. //Казахстан, Алма-Ата.- 1987.- С.111−212.
- Залетаев Д., Немцова М., Стрельников В. и др. Диагностика эпигенетической патологии при наследственных и онкологических заболеваниях // Молекул, биол. — 2004. — Т. 38. С. 213−223.
- Землякова В., Жевлова А., Стрельников В. и др. Аномальное метилирование некоторых генов-супрессоров при спорадическом раке молочной железы // Молекул, биол. — 2003. Т.37. — С. 696−703.
- Имянитов E.H., Хансон К. П. Молекаулярная онкология: клинические аспекты // С.-Пет ербургю- СПб МАПО, — 2007. 211 с.
- Имянитов E.H., Хансон К. П. Эпидемиология и биология рака мочевого пузыря // Практическая онкология, — 2003.- т.4.- № 4, — С. 191−195.
- Копнин Б.П., Копнин П. Б., Хромова Н. В., Агапова Л. С. Многоликий р53: разнообразие форм, функций, опухольсупрессирующих и онкогенных активностей // Онкогематология.- 2008.- Том 1.- № 1С. 2−9.
- Лоран О.Б., Пушкарь Д. Ю., Раснер П. И. Лечение поверхностного рака мочевого пузыря // материалы Российской онкологической конференции, — 27 29 ноября 2001.- г. Москва.- RosOncoWeb — Российский онкологический сервер.
- Матвеев Б.П. Клиническая онкоурология Вердана.// М .- 2003.- С. 197−270.
- Мяндина Л.И., Пягай П. Э., Иткес A.B. и др. Детекция элементов вируса паилломы человека типа 16 в клетках опухолей и периферической крови пациентов, страдающих раком мочевого пузыря.// Медицина, — 2003.-№ 5(24).- С.29−32.
- Степанова Е.В., Барышников А. Ю. Проблемы лекарственной резистентности.// Материалы третьей ежегодной Российской онкологической конференции.-29 ноября -1 декабря 1999 года, Санкт-Петербург
- Хансон К.П., Имянитов Е. Н. Молекулярная генетика рака яичников. //Практич. онкология.- 2000.- № 4, — С.3−6.
- Хасигов П.З., Подобед О. В., Грачёва Т. С. и др.// Биохимия.- 2003.- Вып.7. -С. 869−876.
- Хасигов П.З., Подобед О.В.,. Кцоева С. А и др.// Биохимия.-2001.-Вып.2.-С. 167−179.
- Хейфец В.Х., Хролович А. Б., Каган О. Ф. Фотодинамическое исследование -современный метод раннего выявления и лечения рака мочевого пузыря. // 2004.- ТОМ 5.- С. 16, — С. 258−259.
- Amirghofran Z., Monabati A., Khezri A., Malek-Hosseini Z. Apoptosis in transitional cell carcinoma of bladder and its relation to proliferation andexpression of p53 and bcl-2. // Pathol. Oncol. Res. 2004. — Vol.10(3). — P. 154 158.
- Barghi M.R., Hajimohammadmehdiarbab A., Moghaddam S.M., Kazemi B. Correlation between human papillomavirus infection and bladder transitional cell carcinoma // BMC Infect Dis.- 2005 Nov.- Vol. 8.- N5.- P. 102.
- Baumgart E., Cohen M.S., Silva Neto B., Jacobs M.A. et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors // Clin Cancer Res.- 2007.- Vol. 13.- N6.- P. 1685−1694.
- Bellinsky S. A. et al. Aberrant methylation of pl6 (INK4a) is an early event in lung cancer and potential biomarker for early diagnosis // Proc. Natl. Acad. Sci. USA. — 1998.—Vol. 95.— P. 11 891—11 896.
- Berndt A., Anger K., Richter P. et al. Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder // J Cancer Res Clin Oncol.- 2006.-Aug.- Vol. 132, — N8.- P. 537−546.
- Black P.C., Dinney C.P. Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. // Cancer Metastasis Rev.- 2007.- Vol. 26.- N3−4.- P. 623−634.
- Black P.C., Dinney C.P. Growth factors and receptors as prognostic markers in urothelial carcinoma // Curr Urol Rep. 2008 Jan.- Vol. 9, — N1.- P. 55−61.
- Booth C, Harnden P, Selby PJ, Southgate J. Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder // J Pathol. 2002. — Vol.198 — P.359−368.
- Bose S., Mohammed M., Shintaku P., Rao P.N. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neupolysomy // Breast.- 2002.- Vol.7.- P. 337−344.
- Bourdon J.C. p53 and its isoforms in cancer // Br J Cancer.- 2007.- Vol. 97.- N 3.-P. 277−282.
- Bramhal S.R. The matrix metalloproteinases and their inhibitors in the pancreatic cancer. // Int.J. Pancreatol. -1997. Vol. 21. — P. 1−12.
- Brauers A., Jakse G. Epidemiology and biology of human urinary bladder cancer // J Cancer Res Clin Oncol.- 2000.- Vol. 126.- P. 575−583.
- Bridges AJ. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases // Curr Med Chem.- 1999, — Vol. 6.- P. 825−843.
- Brunner A., Maverl C., Tzankov A., et al. Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. // J. Clin. Pathol. 2004. -Vol.57(9) — P.927−931.
- Bryan R.T., Atherfold P.A., Yeo Y., Jones L.J. et al Cadherin switching dictatesthe biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies //J Pathol.- 2008 .- Vol. 215, — N2, — P. 184−194.
- Byrne R.R., Shariat S.F., Brown R. et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. // J.Urol. 2001 — Vol.165(5) — P.1480.
- Cai M., Onoda K., Nakao M., et al. Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer// Clin Cancer Res. 2002. — Vol.8 — P. 1152−1156.
- Cairns P., Polascik T.J., Eby Y. et al. Frequence of homozygous deletions at p16/CDKN2 in primary human tumors. //Nat Genet.- 1995, — Vol. 11 (2).- P. 210−2.
- Cecchini S., Cipparone I., Confortini M. Urethral cytology of cytobrush specimens// Acta Cytol. 1998. — V.32. — P. 314−317.
- Chaffer C.L., Dopheide B., McCulloch D.R., Lee A.B. et al Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder // Clin Exp Metastasis.- 2005.- Vol. 22,-N2.- P. 115−125.
- Chan S.K., Gullick W.J., Hill M.E. Mutations of epidermal growth factor receptor in non-small cell lung cancer search and destroy // Europ J cancer.- 2006.- Vol. 42.- P. 17−23.
- Charalobopoulos K., Tsambalas S., Syrigos K. at al. Correlation of E-cadherin expression with clinicopathological data in patients suffering from trasitional cell carcinoma of the bladder.// Exp Oncol.-2003.-Vol. 25.-№ 3.- P. 180−185.
- Cherbonnel-Lassere C., Gauny S., Kronenberg A. Supression of apoptpsis by Bcl-2 and Bcl-xL promotes susceptibility to mutegenesis. //Oncogene. -1996. Vol. 13.-P.1489- 1497.
- Chiquet-Ehrismann R. Tenascins, are growing family of extracellular matrix proteins // Experientia. 1995. — Vol.51 — P.853−862.
- Chiquet-Ehrismann R., Chiquet M. Tenascins: regulation and putative functions during pathological stress // J Pathol. 2003. — Vol.200 — P. 488−499.
- Choi Y.D., Cho N.H., Ahn H.S., Cho K.S. et al Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma // J Urol.- 2007.- Vol. 177.- N3.- P. 1174−1178.
- Chuang C.K., Liao S.K. Differential expression of CD44 variant isoforms by cell lines and tissue specimens of transitional cell carcinomas // Anticancer Res.-2003.- Vol. 23, — N6C.- P. 4635−4639.
- Chung K.Y., Shia J., Kemeny N.E. et al. Cetuximab shows activity in colorectal cancer patients with tumors thet do not express the epidermal growth factor receptor by immunohistochemistry// J Clin Oncol.- 2005, — Vol. 23.- P. 1803−1810.
- Colognato H., Yurcenco PD. Form and function: the laminin family of heterotrimers // Dev Dyn. 2000. — Vol.218 — P.213−234.
- Coogan C.L., Estrada C.R., Kapur S. et al. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. // Urology. 2004. — Vol.63(4) — P.786−790.
- Cordon-Cardo C. Mutation of cell gene regulators. Biological and clinical implications for human neoplasia //Am. J. Phatol.- 1995.-Vol. 47.- P. 545−560.
- Dalbagni G., Ren Z., Herr H. et al Genetic alterations in TP53 in recurrent urothelial cancer: a longitudinal study // Clin Cancer Res.- 2001.- Vol.7.- P. 27 972 801.
- Dalbagni S., Presti J. C et al. Genetic alterations in bladder cancer // Lancet. -1994. Vol. 342. — P. 469.
- De Gaetani C., Ferrari G., Righi E. et al // Detection of human papillomavirus DNA in urinary bladder carcinoma by in situ hybridization.- J.Clin.Pathol.- 1999,-Vol.52.- P.103−106.
- De Jong JS, van Diest PJ et al. Expression of growth factors, growth-inhibiting factors and their receptors in invasive breast cancer: correlation with proliferation and angiogenesis. Jour Patholog, 1998- 184: 53−57.
- De Pinieux G., Colin D., Vincent-Salomon A. at al // Virchows Arch. -2004, — May.-Vol.444.-N5.-P.415−9.
- Dekairelle A.F., Tombal B., Cosyns J.P., Gala J.L. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficialtransitional cell carcinoma of the bladder. // Clin. Cancer Res. 2005. -Vol.11(13). — P.4724−4732.
- Dulaimi E. et al. Detection of bladder cancer in urine by tumor suppressor gene hypermethylation paner// Clin. Cancer Res.- 2004. Vol. 10 — P. 1887−1893.
- Dvorak HF. //Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumour angiogenesis and a potential target for diagnosis and therapy // JClin Oncol.-2002.-Vol.20.-P.4368−80.
- Eble J.N., Sauter G., Epstein J.I., Sesterhenn I.A. Tumors of urinary system and male genital organs. Pathology and genetics. // Classification of tumors WHO.-2004.
- Eissa S., Ali-Labib R., Swellam M., Bassiony M. et al Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine II Eur Urol. 2007.- Vol. 52.- N5, — P. 13 961 397.
- Ellsworth P.I., Schned A.R., Heaney J.A. et al. Surgical treatment of verrucous carcinoma of the bladder unassociated with biharzial cystitis: case report and literature review//J Urol.- 1995.-Vol.153.- P.411−414.
- Elsobky E., el Baz M., Gomha M. et al. Prognostic value of angiogenesis in schistosoma-associated squamous cell carcinoma of the urinary bladder // Urology.- 2002.- Vol. 60.- P. 69−73.
- Eltze E., Wulfing C., Von Struensee D. at al // Int J Oncol.- 2005, — Jun.-Vol.26.-N6.-P.1525−31.
- Erill N., Colomer A., Verdu M., Roman R. et al Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression // Diagn Mol Pathol.- 2004.- Vol. 13.- N4, — P. 217−223.
- Friedrich M.G., Dlind C., Milde-Langosch K. et al// Eur. Urol.- 2001, — Vol.40.-P.518−524.
- Gadalla H.A., Kamel N.A., Badary F.A. Elanany FG. Expression of CD44 protein in bilharzial and non-bilharzial bladder cancersn // BJU Int. -2004 Jan.- Vol. 93.-N1.- P.151−155.
- Gaetany C.D., Ferrari G., Righi E. et.al. Detection of human papillomavirus DNA in urinary bladder carcinoma by in situ hybridisation// J.Clin.Pathol. 1999. -V.52. — P. 103−106.
- Galis Z S., Muszynski M., Sukhova GK. Cytokine-stimlated human vascular smooth muscle cells synthesizea complement of enzymes required for extracellular matrix digestion // Circ. Res. -1994. Vol. 75. — P. 181−189.
- Garsia del Muro X., Torregosa A., Munoz J. et al. Prognostic value of the expression of E-cadherin and beta- catenin in bladder cancer.// Eur.J.Cancer -2000 Vol.36(3) — P.357−362.
- Gazzaniga P., Nofroni I., Gandini O., Silvestri I. et al. Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer//Oncol Rep.-2005 Nov.-Vol. 14, — N5, — P. 1199−1202.
- Giaccone G., Rodrigues J.A. EGFR inhibitors: What have we learned from the treatment of lung cancer? // Nat Clin Pract Oncol.- 2005, — Vol. 2.- P. 554−561.
- Gianelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson WG, Quaranta V. Induction of the cell migration by matrix metalloproteinase-2 cleavage of laminin-5 // Science. 1997. — Vol.277 — P.225−228
- Gil P., Allepuz C., Blas M. et al. Significance of protein p53 overexpression in clinical course of high-risk superficial bladder cancer. // Urol.Int. 2003 -Vol.70(3) — P.172−177.
- Guarino M., Rubino B., Ballabio G. The role epithelial-mesenchymal transition in cancer pathology // Pathology.- 2007.- Vol/ 39.- N3.- P. 305−318.
- Hafner C., Knuechel R., Stoehr R., Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies // Int J Cancer.- 2002, — Vol. 101, — N1, — P. 1−6.
- Hafner C., Knuechel R., Zanardo L. et al Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract // Oncogene.- 2001, — Vol. 20.- P. 4910−4915.
- Han J.L., Xie W.L., Huang J., Yao Y.S. Expression of extracellular matrix metalloproteinase inducer in human bladder transitional cell carcinoma. // Ai Zheng. 2003. — Vol.22(11) — P.1158−1161.
- Hanamura N, Yoshida T, Matsumoto E, Kavarada Y, Sakakura T. Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas // Int J Cancer. 1997. — Vol.73 — P.10−15.
- Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HR, Kunze S, Steiner HH. Clinical impact and functional aspect of tenascin-C expression during glioma progression // Int J Cancer. 2002. — Vol.98 — P.362−369
- Herrmann E" Eltze E., Bierer S., Kopke T. et al VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival // Anticancer Res.- 2007.- Vol. 27.- N5A.- P. 3127−3133.
- Herrmann E., Eltze E., Kopke T., Bolenz C. et al New markers for pharmacological targeting in bladder cancer with lymph node metastasis // Aktuelle Urol.- 2007, — Vol. 38, — N5, — P. 392−397.
- Hindermann W., Berndt A., Haas K.M. et al. Immunohistochemical demonstration of gamma2 chain of laminin-5 in urinary bladder urotelial carcinoma. Impact for diagnosis and prognosis.// Cancer Detect. Prev 2003 — Vol.27 (2) — P.109−115
- Hirohashi S. Inactivation of the E-cadheein-mediated cell adhesion system in human cancer//Am. J Pathol. -1998. Vol. 153. — P. 333−339.
- Hirosaki T., Tsubota Y., Kariya Y., et al. Laminin-6 is activated by proteolytic processin and regulates cellular adhesion and migration differently from laminin-5 // Biol Chem. 2002. — Vol.70 — P.498−505
- Hitching A.W., Kumar M., Jordan S. et al. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. // Br. J. Cancer. 2004. -Vol.91 (3) — P.552−557.
- Holmang S., Andius P., Hedelin H. et al. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy // J Urol.- 2001, — Voi. 165.- P. 11 241 128
- Holmang S., Jonasson S.L. The nested variant of transitional cell carcinoma, a rare neoplasm with poor prognosis // Scand J Urol Nephrol.- 2001.- Vol. 35.- P. 102−105
- Hotary K., Allen E., Punhuieri A. Regulation of cell invasion and morphogenesis in a three-dimensional type 1 collagen matrix by membrane-type matrix metalloproteinases 1,2 and 3//J.Cell Biol. -2000. Vol. 149. — P. 1309−1323.
- Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression // Curr Opin Cell Biol.- 2005.- Vol. 17.- N5.- P. 548−558.
- Hussain M., Smith D.C., Al-Sukhum S., et al. Preliminary results of HER-2/neu screening and treatment with Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in patients with advanced urothelial cancer abstract. // Proc ASCO 2002.
- Hussain S.A., Ganesan R., Hiller L. at al // Oncol Rep.- 2003.- May-Jun.-Vol.10,-N3.-P.571−6.
- IARC Molnographs on the Evaluation of Carcinogenesis Risks to Humans. Human Papillomaviruses. Lyon.- 2007.- Vol.90.- P 270−277.
- Iskaros B., Steiberg J.Y., Koss L.G. Tenacsin expression in normal uterine cervix compared with inflammatory and neoplastic lesions // Lab.lnvest. 1998 — Vol.98- N1 -P.105A.
- Iskaros BF., Tanaka KE., Hu X., Kadish AS., Steinberg JJ. Morphologic pattern of tenascin as a diagnostic biomarker in colon cancer // J Surg Oncol. 1997. -Vol.64 — P.98−101.
- Jimenez R.E., Gheiler E., Oscanian P. et al // Am J Surg Pathol.- 2000.- Vol.24.-P.980−987.
- Jimenez R.E., Keane T.E., Hardy H.T. et al // Anatomic Pathology.- 2000.-Jan.-Vol7.- № 1, — P. 13−25.
- Jung Y, Ahmad S, Akagi Y, et al. // Role of the tumour microenvironment in mediating response to anti-angiogenic therapy.- Cancer Metastasis Rev.- 2000.-Vol. 19.- P. 147−157.
- Kashibuchi K., Tomita K., Schalken J.A., Kume H. et al. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy // Int J Urol.- 2007.- Vol. 14.- N9, — P. 789−794.
- Kassouf W., Brown G.A., Black P.C., Fisher M.B. et al Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?//J Urol.- 2008,-Vol. 180, — N.3.- P. 1146−1153.
- Kelman Z. PCNA: structure, functions and interactions Review. // Oncogene. -1997.-Vol.14.-P.629−640.
- Kerbel R, Folkman J. // Clinical translation of angiogenesis inhibitors.- Nat Rev Cancer.- 2002, — Vol. 2.- P. 727−39.
- Kilicli-Camur N. Kilicaslan I., Gulluoglu M.G. et al // Pathol Int.- 2002.-Jul.-Vol.52.-N7.-P.463−9.
- Koksal I.T., Ates M., Danisman A., Sezer C. et al. Reduced E-cadherin and alpha-catenin expressions have no prognostic role in bladder carcinoma // Pathol Oncol Res.-2006.-Vol. 12.-N1.- P. 13−19.
- Korkolopoulou P., Christodoulou P., Lasaris A. et al// Eur. Urol.- 2001.- Vol.39.-P.167−177.
- Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for intracranial ependymoma recurrence: an analysis of 88 cases // J Neurol Sci. -2000.-Vol.177-P.72−82.
- Koss L.G. Mapping of the urinary bladder: its impact on the concepts of bladder cancer// Hum. Pathol. 1979,-Vol. 10, — P. 533−547.
- Kresse H., Schonherr E. Proteoglycans of the extracellular matrix and growth control//J Cell Physiol.-2001.-Vol.189-P.266−274
- Kruger S., Mahnken A., Kausch I., Feller A.C. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. // Eur. Urol. 2005. -Vol.47(4), — P.463−467.
- Kuncova J., Kostrouch Z., Viale M., Revoltella R., Mandys V. Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197 // Folia Biol (Praha).- 2005 Vol. 51.- N1.- P. 3−11.
- Lapham R.L., Grignon D.J., Ro J.Y. Pathologic prognosis parameters in bladder urothelial biopsy, transurethral resection, and cystectomy specimens // Semin Diagn Pathol.- 1997.-Vol. 14.-P. 109−122.
- Latif Z" Waiters A.D., Dunn I. et al // Br J Cancer.- 2003, — Oct.-Vol. 89.-N7.-P.1305−9.
- Latif Z" Waiters A.D., Dunn I. et al // Eur J Cancer.- 2004.- Jan.-Vol.40.-N1.-P.56−63.
- Lee C.C., Yamamoto S., Morimura K. et al. Significance of cyclin D1 overexpression in trasitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. // Cancer 1997. — Vol.79(4) — P.780−789.
- Leng J., Zhang Y" Yao X. et al // Zhonghua Wai Ke Za Zhi.- 2000.- Jan.-Vol.38.-N1.-P.40−3.
- Lievre A., Bachet J.B., Le Corre D. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer // Cancer Res.- 2006.- Vol. 66, — P. 328−331.
- Lin Z., Kim H" Park H. et al // Urol Res.- 2003.- Aug.-Vol.31 .-N4.-P.272−5.
- Liotta L.A., Stetler-Stevenson W.G.Tumor invasion and metastsis: An imbalance of positive and negative regulation. //Cancer Res. -1991. Vol. 51,(Supp2). — P. 5054−5059.
- Liu L., Zhu D., Gao R., Guo H. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder // Urol Int.- 2008.- Vol. 81.- N1.- P. 72−76.
- Lopez Beltran A., Escudero A.L. Human pappilomavirus and bladder cancer// Biomed. Pharmacother. -1997. -V.57.-P. 252−257.
- Lopez Beltran A., Pacelli A., Rothenberg H. J et al. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological stady of 41 cases // J Urol.-1998,-Vol. 159.- P. 1497−1503
- Lowe S.W., Sherr C.J.// Curr.Opin.Genet.Dev.- 2003.- Vol.13, — P.77−83.
- Ludwig M., Kochel H. G, Fisher C et.al. Human papilloma virus in tissue of bladder and bladder carcinoma spesimens// Eur.Urol. 1996. — V.30. — P.96- -102.
- Lynch T.J., Bell D.W., Sordella L. et al. Activating mutations in the epidermal growth factor receptor underling responsiveness of non-small-cell lung cancer to gefitinib//New Engl J Med.-2004.-Vol. 350.- P. 2129−2139.
- Malats N, Bustos A, Nascimento CM et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review.// Lancet Oncol. -2005.-Vol. 6.-P. 678−86.
- McDonnell T. J, Becham A., Sarkiss M. Importance of the Bcl-2 family in cell death regulation // Experential Biol. 1996. — Vol. 52. — P. 1008−1017.
- Mian C, Lodde M., Comploj E. et al. Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. //J Clin Pathol.- 2006.- Vol. 59(9).- P. 984−987.
- Michael W. Y. et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients // Clin. Cancer Res. 2002.- Vol. 8.- P.464−470.
- Monier F., Mollier S., Guillot M., Rambeaud J.J. et al Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas II Eur Urol.- 2002.- Vol. 42, — N4, — P. 356−363.
- Moroni A., Veronese S., Benvenuti S. et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cogjiort study // Lancet Oncol.- 2005.- Vol. 6.- P. 279−286.
- Mostofi F.K., Davis C.J., Sesterhenn I .A. Histological typing of urinary bladder tumors // Int. Histological Classification of Tumors. Second Tdition. — WHO. — 1999.
- Moyano Calvo J.L., Blanco Palenciano E., Beato Moreno A., Gutierrez Gonzalez M. et al. Prognostic value of E-cadherina, beta catenin, Ki-67 antigen and p53 protein in the superficial bladder tumors // Actas Urol Esp. 2006 Vol. 30.- N9.-P. 871−878.
- Murphy W.M., Beckwith J.B., Farrow G.M. Tumors of the kidney, bladder, and related urinary stryctures // Atlas of tumor pathology. AFIP. -1994.
- Nakopoulou L., Mylona E., Papadaki I. et al. Study of phosphor-p-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. // Modern Pathologi. 2006. — Vol.19. — P.556−563.
- Nakopoulou L., Zervas A., Gakiopoulou-Givalou H. et al. Prodnostic value of. E-cadherin, beta- catenin, P120ctn in petients with transitional cell bladder cancer. // Anticancer Res. 2000 — Vol.20(6B) — P.4571−4578.
- Nakopoulov L., Panayotopoulou E.G., Giannopoulen J. et al. Stromelysin-3 protein expression in invasive breast cancer: relation to proliferation, cell survival and patients outcome. // Mod. Pathol. 2002. — Vol.15, № 11. — P.1154−1161.
- Nathanson S.D. Preclinical models of regional lymph node tumor metastasis // Cancer Treat Res.- 2007.-Vol. 135.- P. 129−156.
- Nichols G.E., Williams M.E., Gaffey M.J., Stoler M.H. Cyclin D1 gene expression in human cervical neoplasia. // Modern Pathologi. 1996. — Vol.9. — P.418−425.
- Okamoto I., Kawano Y., Tsuiki H. et al. CD44 cleavage induced by membrane-associated metalloproteinase plays a critical role in tumor cell migration // Oncogene 1999 — Vol. 18 — N7 — P. 1435−1446
- Oliver M., Hainaut P., Borresen-Dale A.L. Prognostic and predictive value of TP53 mutations in human cancer/ In: 25 Years of p53 Research, Ed. by P. Hainaut and K.G. Wiman. // Springer, Dardrecht-Berlin-Hedelberg-New York.- 2005, — P.321−338.
- Ong E., Moonen L.M., Gallee M.P. et al. Prognostic factors in transitional cell carcinoma of bladder: an emerging role for Bcl-2 and p53. // Radiother.Oncol. -2001 Vol.61(2) — P.169−175.
- Paez J.G., Janne R.A., Lee J.C. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy // Science.- 2004.- Vol. 304.- P. 14 971 500.
- Papathoma A.S., Petraki C., Grigorakis A. et al. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. // Anticancer Res. 2000 -Vol.20(3B) — P.2009−2013.
- Park T.W., Fujiwara H., Wright T.C. Molecular biology of cervical cancer and its precursors//Cancer. 1995. -Vol.76.-P. 1902−1913.
- Parkin D.M., Whelean S.L., Ferlai J. et al // 2003, N155. IARC Press: Lyon
- Paterson F.R., Ulbright Th.M., MacLennan G.T. et al Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma // Am Cancer Society.- 2003.- Vol.98.- N8.- P. 1830−1836.
- Paunesku T., Mittal S., Proctic M. et al. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome.// Int. j. Radiat. Biol. 2001. — Vol.77. — P. 1007−1021.
- Perry J.E., Grossmann M.E., Tindall D. J. Epidermal growth factor induces cyclin D1 in human prostate carcer cell line. // Prostate. -1998. Vol.35{2) — P.117−124.
- Petitjean A., Achatz M.I., Borresen-Dale A.L. et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes // Oncogene.- 2007.- Vol. 26.- N15.- P. 2157−2165.
- Ponta H., Sherman L., Herrlich P.A. CD44: From adhesion molecules to signallig regulators // Nat Rev Mol Cell Biol. 2003.- Vol 4, — N 1.- P. 33−45.
- Potter E., Bergwitz C., Brabant G. The cadherin-catenin system: implications for growth and differentiation of endocrine tissues // End. Rev. -1999. -Vol. 20, N2. -P. 207−239.
- Prat E. et al. // Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization // Urology. 2001. — Vol. 57. — P. 986−992.
- Raghavan D., Shipley W.U., Garnick M.B. et al // N Engl J Med.-1990.-Vol. 322,-P. 1129−1138.
- Rodriguez-Alonso A., Pita-Fernandez S., Gonzalez-Carrero J. et al // Cancer.-2002.-Vol. 94.-P. 1677−1684.
- Rotterud R., Fossa S.D., Nesland J.M. Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium // Histol Histopathol.- 2007 Apr.- Vol. 22.- N4.- P. 349 363.
- Rotterud R., Nesland J.M., Berner A., Fossa S.D. Expression of the epidermal growth receptor family in normal and malignant urothelium. // BJU Int. 2005. -Vol.95(9) — P.1344−1350.
- RuasM., Peters G.//Biochim. Biophys. Acta.- 1998.-Vol.1378.-P.115−177.
- Sablina A.A., Chumakov P.M., Kopnin B.P. Tumor suppressor p53 and its gomologue p73alpha affect cell migration // J Biol Chem.- 2003.- Vol. 278.- N30,-P. 27 362−71.
- Salomon DS, Brandt R et al. Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol, 1995- 19: 183−232.
- San Miguel Fraile P., Gomez de Maria C., Donis Quintairos L., Carrera Vazquez A. et al. Expresion of E-cadherin and catenins in urothelial carcinomas // Actas Urol Esp. 2007, — Vol. 31.- N4.- P. 355−360.
- Savelieva E., Belair CD., Newton M.A. et.al. 20q gain associates with immortalization: 20ql3.2 amplification correlates with genome instability in human uroepithelial cells// Oncogene. 1997.-V. 14. -P. 551 -560.
- Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown // J Cell Physiol. 2000. — Vol.182 — P.311−322
- Seargent J.M., Loadman P.M., Martin S.W. at al. Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma // Urology.-2005.- Apr.-Vol.65.-N4.-P.815−20.
- Serrano M" Hannon G., Beach D./l Nature.-1993, — Vol.366.- P.704−707.
- Soini Y., Paakko P., Nuorva K., et al. Tenascin immunoreactivity in lung tumors // Am J Clin Pathol. 1993. — Vol.100 — P.145−150.
- Sokolova LA., Hailing K.C., Tenkins R.B. et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. // J Mol Diagn.- 2000, — Vol. 2(3).- P.116−23.
- Spessoto P., Yin Z., Magro G., et al. // Laminin isoforms 8 and 10 are primary components of the subendothelial basement membrane promoting interaction with neoplastic lymphocytes // Cancer Res. 2001. — Vol.61 — P.339−347
- Spruk C et al. //Two molecular pathways to transitional cell carcinoma of the bladder // Cancer Res. — 1994. — Vol. 54. — P.784−788.
- Stacker A, Baldwin M.E., Achen M.G. // The role of lymphangiogenesis in metastatic spread. FASEB J.- 2002, — Vol. 16.- P. 922−34.
- Staunton M. J., Gaffney E. Tumor type is a development of susceptibility to apoptosis // Anat. Pathol. -1995. Vol.103. — P. 300−307.
- Stauropoulos N.E., Filiadis I., loachim E. et al. Prognostic significance of p53, bcl-2, Ki-67 in high-risk superficial bladder cancer. // Anticancer Res. 2002 -Vol.22(6B) — P.3759−3764.
- Stieve T. The p53 family in differentiation and tumorogenesis // Nat Rev Cancer.-2007.- Vol. 7.- N3.- P. 165−168.
- Su J.S., Arima K., Hasegawa M. et al // Hinyokika Kiyo. -2003.- Nov.-Vol.49.-N11 .-P.649−58.
- Sumi T., Yoshida H., Hyun Y. et al. Expression of matrix metalloproteinases in human transitional cell carcinoma of urinary bladder. // Oncol.Rep. 2003 -Vol.10(2) — P.435−349.
- Sundar S.S., Ganesan T.S. Role of lymphangiogenesis in cancer// J Clin Oncol.-2007.- Vol. 25, — N27.- P. 4298−4307.
- Takeichi M.. The cadherins: Cell-cell adhesion molecules controling animal morphogenesis // Development. 1988. — Vol. 102. — P. 639−655.
- Takeichi M. Cadherine-cell adhesion receptor as morphogenetic regulator // Science. -1991. Vol. 251. — P. 1451−1455.
- Tang D.G., Porter AT. Apoptosis: A current molecular analysis // Oncology Research. 1996. — Vol.3, N30. — P. 117−131.
- Taraboletti G., D’Ascerzo S., Borsotti P. Shedding of the Matrix Mettalloproteases MMP-2, MMP-9 and MT1-MMP as Membrane Vesicl-Associated Components by Endotelice Cells // Am.J.Pathol. 2002. — Vol.160. — P.673−680.
- Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells // Nature. 1999. — Vol.398 — P.422−426
- Timple R. Macromolecular organization of basement membrane // Curr. Opin. Cell Biol. 1996. -Vol. 8. — P. 618−624.
- Todderud G, Carpenter G. Epidermal growth factor: the receptor and its function. Bio Factors 1989- 2: 11−15.
- Trkova M., Babjuk M., Duskova J. et al Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer // Cancer Lett.- 2006, — Vol. 242.- N1.- P. 68−76.
- Tsai Y.S., Tzai T.S., Chow N.H. at al // Urol Int.- 2003.-Vol.71.-N3.-P.262−70.
- Tsutsumi M., Tsai Y.C., Gonsalgo M.L. et al// Oncogene.- 1998.- Vol.17.- P.3021−3027.
- Tut V.M., Braithwaite K.L., Angus B. et al. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, wafl, pRb and Ki-67. // Br.J.Cancer 2001 — Vol.84(2) — P.270−275.
- Vasala K., Kuvaja P., Turpeenniemi-Hujanen T. Low Circulating Levels of ProMMP-2 Are Associated with Adverse Prognosis in Bladder Cancer // Tumour Biol. 2008, — Vol. 29.- N5.- P. 279−286.
- Vasala K., Paakko P., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. // Urology. -2003. Vol.62(5) — P.952−957.
- Vogelstein B., Kinzler K.W. The genetic basis of human cancerl.// McGraw-Hill Medical Pablishing Division.- 2002. P. 697−702.
- Vu T.H., Werb Z. Matrix metallproteinases: Effectors of development and normal physiology// Genes&Development. 2000. -Vol.14. — P. 2123−2133.
- Wallard M.J., Pennington C.J., Veerakumarasivam A., Burtt G. et al Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma // Br J Cancer.- 2006, — Vol. 94.- N4.- P.569−77.
- Wang C., Liu X., Wang L., at al p16, p53 and c-erbB-2 gene expression in bladder carcinoma // Zhonghua Bing Li Xue Za Zhi. -2000, — Feb.-Vol.29.-N1 .-P.20−3.
- Werb Z. ECM and cell surface proteolysis regulating cellular ecology // Cell. -1997. Vol.91 — P.439−442
- Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther, 1999- 82: 241−250
- Wulfing C., von Struensee D., Bierer S., Bogemann M., Hertie L., Eltze E. Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy // Aktuelle Urol. 2005 Sep.- Vol. 36.- N5.- P. 423−429.
- Xu K., Hou S., Du Z. Prognostic value of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in bladder carcinoma // Chin Med J (Engl).- 2002.-Vol. 115, — N5.- P. 743−745.
- Yang C.C., Chu K.C., Chen H.Y., Chen W.C. Expression of p16 and cyclin D1 in bladder cancer and correlation in cancer progression. // Urol.Int. 2002 -Vol.69(3) — P.190−194.
- Yano A., Nakamoto K., Hashimoto K., Usui T. Localization and expression of tissue inhibitor of metalloproteinase 1 in human urotelial carcinoma. // J.Urol. -2002 — Vol.167(2Pt.1) — P.729−734.
- Zeng Z.S., Cohen A.M., Guillem J.G. Loss of basement membrane type IY is associated with increased expression of metalloproinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis // Carcinogenesis. 1999.- Vol. 20, N 5. — P. 749−755.
- Zhou M., Magi-Galluzzi C. Genitourinary pathology // 2007.- Churchill Livingstone Elsevier.
- Zigeuner R., Tsybrovskyy O., Ratschek M., Rehak P. // Urology.- 2004.- Jun.-Vol.63.-N6.-P. 1079−83.
- Zu X., Tang Z., Li Y., Gao N., Ding J., Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis // BJU Int. 2006.- Vol. 98.- N5.- P. 1090−1093.